PharmTech Drug Digest 11.20

Devyn Smith, PhD

Devyn Smith, PhD, is chief operations officer and head of strategy of Sigilon Therapeutics.

Articles by Devyn Smith, PhD

Researchers at MIT have discovered a new set of compounds that do not elicit a foreign body response when implanted. These biomaterials permit the development of a new category of treatment with the ability to deliver therapeutics either at a constant rate or under programmable conditions by using implantable cells as protein factories.